Literature DB >> 2020750

Hypofractionation: lessons from complications.

G H Fletcher1.   

Abstract

Hypofractionation refers to irradiation schemes with less than 5 fractions per week and larger doses per fraction than 2 Gy. It was initiated around 1960 to ease the burden for patients who had to come to the hospital to be treated every day and to save machine time. In the treatment of breast cancer at the University of Texas M.D. Anderson Cancer Center (UTMDACC) in 1962, the acute reactions of the skin were matched in 3- and 5-day treatment. More severe late sequelae were observed in the 3-day-a-week treatment than in the 5-day treatment. In 1966 the NSD formula was published and from thereon was used to adjust the total dose based on the number of fractions. Later, the TDF and CRE formulae were used. In almost all publications, a high percentage of severe complications after hypofractionation have been reported. There is overwhelming evidence that fraction size of more than 2 Gy produces late unfavorable sequelae, and therefore, despite the inconvenience for patients and the taxing of machine time, hypofractionation should not be used, unless there is a specific rationale concerning the tumor characteristics of doing so. In that case the total dose must be corrected in order not to increase the late morbidity.

Entities:  

Mesh:

Year:  1991        PMID: 2020750     DOI: 10.1016/0167-8140(91)90106-q

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

1.  Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation-induced dermatitis in breast cancer patients.

Authors:  T Hijal; A A Al Hamad; T Niazi; K Sultanem; B Bahoric; T Vuong; T Muanza
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

2.  Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer.

Authors:  Robert D Timmerman; Chen Hu; Jeff M Michalski; Jeffrey C Bradley; James Galvin; David W Johnstone; Hak Choy
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

3.  Single high-dose vs. fractionated radiotherapy: Effects on plant growth rates.

Authors:  Marc Guedea; Antoni Castel; Marc Arnalte; Alex Mollera; Victor Muñoz; Ferran Guedea
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-24

4.  Tracing the earliest medical uses of high dose-per-fraction external beam radiation.

Authors:  Brian D Kavanagh
Journal:  J Radiosurg SBRT       Date:  2011

Review 5.  Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

Authors:  Robert D Timmerman; Joseph Herman; L Chinsoo Cho
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 6.  The evolution of the locoregional therapy of breast cancer.

Authors:  Alice Ho; Monica Morrow
Journal:  Oncologist       Date:  2011-09-29

7.  Radiation-induced cognitive impairment and altered diffusion tensor imaging in a juvenile rat model of cranial radiotherapy.

Authors:  Ann M Peiffer; Rebecca M Creer; Constance Linville; John Olson; Praveen Kulkarni; Jacquelyn Ann Brown; David R Riddle; Mike E Robbins; Judy E Brunso-Bechtold
Journal:  Int J Radiat Biol       Date:  2014-08-11       Impact factor: 2.694

8.  Comparison of the response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules.

Authors:  S Appold; M Baumann; C Petersen; K Horn; F Eichhorn
Journal:  Strahlenther Onkol       Date:  1998-06       Impact factor: 3.621

Review 9.  Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Wilfried Budach; Edwin Bölke; Christiane Matuschek
Journal:  Breast Care (Basel)       Date:  2015-08-19       Impact factor: 2.860

10.  Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.

Authors:  Dong Soo Lee; Yeon Sil Kim; Jae Seok Cheon; Jin Ho Song; Seok Hyun Son; Ji Sun Jang; Young Nam Kang; Jing Hyoung Kang; So Lyoung Jung; Ie Ryung Yoo; Hong Seok Jang
Journal:  Radiat Oncol       Date:  2012-06-12       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.